# Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma

> **NCT01774253** · PHASE2 · TERMINATED · sponsor: **Giselle Sholler** · enrollment: 9 (actual)

## Conditions studied

- Pontine Glioma

## Interventions

- **DRUG:** Vismodegib

## Key facts

- **NCT ID:** NCT01774253
- **Lead sponsor:** Giselle Sholler
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Lack of enrollment and commercial availability of drug
- **Last updated:** 2024-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01774253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01774253, "Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01774253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*